Literature DB >> 4764375

Lack of biological interaction of alprenolol and salicylate in man.

G Johnsson, C G Regårdh, L Sölvell.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4764375     DOI: 10.1007/bf00561794

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man.

Authors:  G Levy; T Tsuchiya; L P Amsel
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

2.  Absorption of alprenolol in man from tablets with different rates of release.

Authors:  R Johansson; C G Regårdh; J Sjögren
Journal:  Acta Pharm Suec       Date:  1971-03

3.  Drug biotransformation interactions in man. I. Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man.

Authors:  G Levy; J A Procknal
Journal:  J Pharm Sci       Date:  1968-08       Impact factor: 3.534

4.  Gas chromatographic determination of the secondary amine alprenolol, as its trifluoroacetyl derivative, at nanogram levels in biological fluids.

Authors:  M Ervik
Journal:  Acta Pharm Suec       Date:  1969-06

5.  Drug biotransformation interactions in man. V. Acetaminophen and salicylic acid.

Authors:  G Levy; C G Regårdh
Journal:  J Pharm Sci       Date:  1971-04       Impact factor: 3.534

6.  Potency and time effect relationship in man of propranolol and H 56-28. I. Comparative studies after intravenous administration. II. Studies on the ratio of equipotent oral and intravenous doses.

Authors:  G Johnsson; A Norrby; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1967
  6 in total
  6 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 2.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

3.  Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.

Authors:  C S Deacon; M S Lennard; N D Bax; H F Woods; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 5.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Authors:  P H Hinderling; O Schmidlin; J K Seydel
Journal:  J Pharmacokinet Biopharm       Date:  1984-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.